Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
A Roche director joins predictive drug discovery firm Compugen and a Bristol-Myers Squibb exec is welcomed at immuno-oncology company Turnstone Biologics – both in Business Development. And China- and US-based biopharma Antegene brings on Celgene manager as CBO.
The CEO of Ipsen Group departs to take top job at new gene therapy company FerGene and Novo Nordisk’s VP, regulatory affairs moves to EVP, quality and regulatory at Scandinavian orthobiologics firm BoneSupport. At commercial-stage pharma business PDL BioPharma, a chairperson is elected.
New CEOs for Abgenomics, Advangen, Dynavax Technologies, Merus and Nuvelution are among the latest biopharma appointments. Kiadis Pharma’s CFO’s resignation takes effect on 31 December.
Khondrion BV, developer of therapies for mitochondrial disease, has appointed a former Novartis SVP as COO, and pain and inflammation medicines firm Grunenthal GmbH to promote acting CSO to CSO and director. Also, Royal DSM NV says CEO to resign in February.
The new Ferring-backed gene therapy company has bagged a big name player in David Meek as its CEO but the move has created a void at the top for France's Ipsen.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
Executives On The Move: Comings And Goings At JSC Olainfarm And MorphoSys, Plus A Promotion At Twist Bioscience
Latvian pharma producer JSC Olainfarm picks next CEO and chairman, and CSO is scheduled to depart German therapeutic antibody company MorphoSys. Meanwhile, synthetic DNA manufacturer Twist Bioscience promotes SVP to chief commercial officer.
Richard Torbett, who negotiated the UK's new voluntary pricing scheme, is to be the new chief executive of the ABPI.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Roche's India head, Lara Bezerra, seen as unconventional in her overall strategic approach, is heading out of the company. Speculation is rife that questions around "business deliverables" may have contributed to the decision.
Executives On The Move: A Finance And Development Change At EyePoint Pharma And Exits At PPD And Novartis
Ophthalmology biopharma EyePoint Pharmaceuticals confirms its new CFO and head of corporate development. A former PPD med director is now CMO of vaccine developer ILiAD Biotechnologies and neurological disorders firm Ovid Therapeutics adds ex-Novartis VP as chief commercial officer.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.